PARP Cancer Research Results

PARP, poly ADP-ribose polymerase (PARP) cleavage: Click to Expand ⟱
Source:
Type:
Poly (ADP-ribose) polymerase (PARP) cleavage is a hallmark of caspase activation. PARP (Poly (ADP-ribose) polymerase) is a family of proteins involved in a variety of cellular processes, including DNA repair, genomic stability, and programmed cell death. PARP enzymes play a crucial role in repairing single-strand breaks in DNA.
PARP has gained significant attention, particularly in the treatment of certain types of tumors, such as those with BRCA1 or BRCA2 mutations. These mutations impair the cell's ability to repair double-strand breaks in DNA through homologous recombination. Cancer cells with these mutations can become reliant on PARP for survival, making them particularly sensitive to PARP inhibitors.
PARP inhibitors, such as olaparib, rucaparib, and niraparib, have been developed as targeted therapies for cancers associated with BRCA mutations.

PARP Family:
The poly (ADP-ribose) polymerases (PARPs) are a family of enzymes involved in a number of cellular processes, including DNA repair, genomic stability, and programmed cell death.
PARP1 is the predominant family member responsible for detecting DNA strand breaks and initiating repair processes, especially through base excision repair (BER).

PARP1 Overexpression:
In several cancer types—including breast, ovarian, prostate, and lung cancers—elevated PARP1 expression and/or activity has been reported.
High PARP1 expression in certain cancers has been associated with aggressive tumor behavior and resistance to therapies (especially those that induce DNA damage).
Increased PARP1 activity may correlate with poorer overall survival in tumors that rely on DNA repair for survival.
Scientific Papers found: Click to Expand⟱
8156- lamb,    A review on chemistry, source and therapeutic potential of lambertianic acid
- Review, Var, NA
*Obesity↓, *AntiCan↑, *AMPK↑, *β-HEX↓, NA↑, TumCCA↑, AMPK↑, ACC↑, p‑Akt↓, FOXM1↓, CycB/CCNB1↓, XIAP↓, Bcl-2↓, p‑STAT3↓, p‑NF-kB↓, Bcl-xL↓, survivin↓, VEGF↓, COX2/PTGS2↓, cMyc↓, IL6↓, TNF-α↓, ROS↑, STK11/LKB1↑, cl‑Casp3↑, cl‑PARP↑, Synergy↑, AR↓, TumCP↓, p‑P53↓, P21↓, p27/CDKN1B↓, cycD1/CCND1↓, CDK4↓, PSA↓, STAT3↓, ac‑p65↓, *antiAll↑,
2351- lamb,    Anti-Warburg effect via generation of ROS and inhibition of PKM2/β-catenin mediates apoptosis of lambertianic acid in prostate cancer cells
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
proCasp3↓, proPARP↓, LDHA↓, Glycolysis↓, HK2↓, PKM2↓, lactateProd↓, p‑STAT3↓, cycD1/CCND1↓, cMyc↓, β-catenin/ZEB1↓, p‑GSK‐3β↓, ROS↑, eff↓, Warburg↓,
8161- LapC,    Lapachol is a novel ribosomal protein S6 kinase 2 inhibitor that suppresses growth and induces intrinsic apoptosis in esophageal squamous cell carcinoma cells
- in-vitro, ESCC, KYSE-30 - in-vitro, ESCC, KYSE450 - in-vitro, ESCC, KYSE-510
RSK2/RPS6KA3/p90RSK2↓, TumCG↓, Apoptosis↑, Casp3↑, Casp7↑, PARP↑, Cyt‑c↑, BAX↑, p‑CREB↓, ATF1↓, H3↓, CycB/CCNB1↓, cycD1/CCND1↓, p‑CDK2↓,
8175- Las,    Lasiodin Inhibits Proliferation of Human Nasopharyngeal Carcinoma Cells by Simultaneous Modulation of the Apaf-1/Caspase, AKT/MAPK and COX-2/NF-κB Signaling Pathways
- in-vitro, NPC, NA
tumCV↓, TumCMig↓, APAF1↑, Cyt‑c↑, cl‑PARP↑, cl‑Casp3↑, cl‑Casp9↑, Apoptosis↑, p‑Akt↓, p‑ERK↓, p‑p38↓, p‑JNK↓, COX2/PTGS2↓, NF-kB↓, chemoPv↑,
8249- LCA,    Induction of C/EBP homologous protein-mediated apoptosis and autophagy by licochalcone A in non-small cell lung cancer cells
- in-vitro, NSCLC, NA
tumCV↓, LDH↑, Apoptosis↑, selectivity↑, LC3II↑, TumAuto↑, ER Stress↑, CHOP/DDIT3↑, chemoP↑, RenoP↑, cl‑PARP↑, cl‑Casp7↑, cl‑Casp3↑,
8237- LCA,    Role of Licochalcone A in Potential Pharmacological Therapy: A Review
- Review, Var, NA
*other↝, *Inflam↓, *Bacteria↓, *antiOx↑, *AntiP↑, *neuroP↑, *glucose↝, *lipid-P↓, PKCδ↓, P70S6K↓, Akt↓, ER Stress↑, Apoptosis↑, Ca+2↑, PI3K↓, mTOR↓, Casp3↑, Bcl-2↓, Cyt‑c↑, BAX↑, cl‑PARP↑, cycD1/CCND1↑, ROS↑, CHOP/DDIT3↑, ERK↑, p38↑, JNK↓, IAP1↓, XIAP↓, survivin↓, cFLIP↓, RIP1↓, EGFR↓, MET↓, HER2/EBBR2↓, p‑4E-BP1↓, PERK↑, eIF2α↑, PD-L1↓, HK2↓, Glycolysis↓, Sp1/3/4↓, FasL↑, MMP↓, ATP↓, TumAuto↑, WEE1↑, P21↑, CDK1↓, TumCCA↑, TumCMig↓, TumCI↓, ABCG2↓, HSP90↓, T-Cell↑, CD4+↑, CD25+↑, FOXP3↑, Imm↝, *Inflam↓, *NF-kB↓, *NRF2↑, *AntiArt↑, *antiAll↑, *MUC5AC↓, *E-sel↓, *CCL11↓,
8248- LCA,    Licochalcone A Inhibits the Proliferation of Human Lung Cancer Cell Lines A549 and H460 by Inducing G2/M Cell Cycle Arrest and ER Stress
- in-vitro, NSCLC, A549 - in-vitro, Lung, H460
tumCV↓, TumCG↓, TumCCA↑, MDM2↓, CycB/CCNB1↓, cDC2↓, CDC25↓, Casp3↑, PARP↑, ER Stress↑, p‑eIF2α↑, ATF4↑, TumCP↓, selectivity↑, Bcl-xL↓, Bcl-2↓,
8241- LCA,    Licochalcone A induces apoptotic cell death via JNK/p38 activation in human nasopharyngeal carcinoma cells
- in-vitro, NPC, NA
tumCV↓, Apoptosis↑, Casp8↑, Casp9↑, Casp3↑, cl‑PARP↑, ERK↑, p38↑, JNK↑, *antiAll↑, *Bacteria↓, *Inflam↓, *antiOx↑, *AntiCan↑,
8259- LCA,    Modulation of bcl-2 and cytotoxicity by licochalcone-A, a novel estrogenic flavonoid
- in-vitro, BC, MCF7 - in-vitro, AML, HL-60
ChemoSen↑, Apoptosis↑, cl‑PARP↑, Bcl-2↓, Bax:Bcl2↑,
8206- LCA,    Licochalcone A-induced human gastric cancer BGC-823 cells apoptosis by regulating ROS-mediated MAPKs and PI3K/AKT signaling pathways
- in-vivo, GC, BGC-823
ROS?, Casp3↑, cl‑PARP↑, eff↓, ERK↑, JNK↑, MAPK↑, AntiP↑, AntiTum↑, TumCP↓, selectivity↑, GSH/GSSG↓, MDA↑, lipid-P↑, PI3K↓, Akt↓,
8235- LCA,    Anticancer effects of licochalcones: A review of the mechanisms
- Review, Var, NA
mt-Apoptosis↑, TumAuto↑, TumCMig↓, LC3‑Ⅱ/LC3‑Ⅰ↑, ATG5↑, ATG7↑, p62↑, CHOP/DDIT3↑, ER Stress↑, UPR↑, ATG3↑, Beclin-1/ATG6↑, ATG16L1↑, PERK↑, ATF4↑, ATP↓, Hif1a↓, GLUT1↓, PDK1 / PDPK1↓, Bcl-xL↓, Bcl-2↓, BAD↑, BAX↑, Casp3↑, survivin↓, EGFR↓, ERK↓, Akt↓, mtDam↑, MMP↓, Cyt‑c↑, Casp↑, MDM2↓, CycB/CCNB1↓, CDC2↓, CDC25↓, TumCCA↑, TumCP↓, Wnt↓, β-catenin/ZEB1↓, Sp1/3/4↓, MMP-10↓, MMP3↓, TumCI↓, Imm↑, PD-L1↓, ROS↑, 4E-BP1↓, eIF2α↓, PI3K↓, mTOR↓, p‑cMET↑, Ca+2↑, RUBCN↓, ATG13↑, TSC1↑, TSC2↑, PRAS40↑, PP2A↑, ULK1/ATG1↑, THEM4/CTMP↑, DR5↑, Fas↑, TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1↑, PKCδ↓, P70S6K↓, VEGF↓, angioG↓, HK2↓, Glycolysis↓, TrxR1↓, APAF1↑, cl‑PARP↑, Bax:Bcl2↑, ABCG2↓, BioEnh↑,
8210- LCA,    Licochalcone A-Induced Human Bladder Cancer T24 Cells Apoptosis Triggered by Mitochondria Dysfunction and Endoplasmic Reticulum Stress
- in-vitro, Bladder, T24/HTB-9
chemoPv↑, TumCP↓, ROS↑, Apoptosis↑, mtDam↑, Casp3↑, cl‑PARP↑, ER Stress↑, GRP78/BiP↑, CHOP/DDIT3↑, Casp12↑, mt-ROS↑, tumCV↓, GSH/GSSG↓, NA↓,
8337- LDN,    Low-dose naltrexone inhibits colorectal cancer progression and promotes apoptosis by increasing M1-type macrophages and activating the Bax/Bcl-2/caspase-3/PARP pathway
- in-vitro, CRC, NA
OGFr↑, BAX↑, Casp9↑, Casp3↑, PARP↑, Bcl-2↓, survivin↓, Ki-67↓, Apoptosis↑,
8288- LE,    18 β-glycyrrhetinic acid exhibits potent antitumor effects against colorectal cancer via inhibition of cell proliferation and migration
- vitro+vivo, CRC, NA
TumCP↓, survivin↓, cl‑PARP↑, TumCMig↓, Wound Healing↓, TumCI↓, MMPs↓, p‑PI3K↓, p‑Akt↓, p‑STAT↓,
8236- LE,    Licorice (Glycyrrhiza glabra L.)-Derived Phytochemicals Target Multiple Signaling Pathways to Confer Oncopreventive and Oncotherapeutic Effects
- Review, Var, NA
Bcl-2↓, CDK2↓, PI3K↓, cJun↓, mTOR↓, NF-kB↓, VEGF↓, MMP3↓, toxicity↓, Dose↑, chemoP↑, *antiOx↑, *Inflam↓, Dose↝, *COX2/PTGS2↓, *iNOS↓, *IL6↓, *IL10↓, *PGE2↓, *IκB?, *NRF2↑, *HO-1↑, *lipid-P↓, *ROS↓, *Catalase↑, *GPx↑, *SOD↑, Apoptosis↑, ROS↑, TumCP↓, TumCCA↑, cycE/CCNE↓, cycD1/CCND1↓, p‑GSK‐3β↓, PI3K↓, MKK4↓, MKK7↓, HSP90↓, LC3‑Ⅱ/LC3‑Ⅰ↑, Beclin-1/ATG6↑, p62↓, p‑Akt↓, cl‑Casp9↑, cl‑Casp7↑, cl‑Casp3↑, cl‑PARP↑, BAX↑, Cyt‑c↑, P53↑, STAT3↓, E-cadherin↑, Vim↓, N-cadherin↓, CD31/PECAM-1↓, Hif1a↓, iNOS↓, DNAdam↑, MMP↓, BIM↑, APAF1↑, PCNA↓, toxicity↝, eff↑,
8282- LE,    Glycyrrhizic Acid Inhibits Proliferation of Gastric Cancer Cells by Inducing Cell Cycle Arrest and Apoptosis
- in-vitro, GC, MGC803 - in-vitro, GC, BGC-823 - in-vitro, GC, SGC-7901
Ingr↝, TumCP↓, TumCCA↑, Apoptosis↑, cycD1/CCND1↓, cycE/CCNE↓, BAX↑, PARP↑, proCasp3↑, proCasp8↑, proCasp9↑, Bcl-2↓, survivin↓, p65↓, p‑PI3K↓, p‑Akt↓,
8277- LE,    Oncopreventive and oncotherapeutic potential of licorice triterpenoid compound glycyrrhizin and its derivatives: Molecular insights
- Review, Var, NA
*antiOx↑, *AntiTum↑, HMGB1↓, COX2/PTGS2↓, PGE2↓, TumCP↓, TumCCA↑, Synergy↑, MMP↓, p‑P53↑, BAX↑, cl‑PARP↑, proCasp3↑, proCasp8↑, proCasp9↑, ROS↑, TumAuto↑, MMP9↓, TumMeta↓, PI3K↓, Akt↓, eff↑, *chemoP↑, *NRF2↑, *NF-kB↓,
8279- LE,    18β-Glycyrrhetinic Acid Has Anti-Cancer Effects via Inducing Apoptosis and G2/M Cell Cycle Arrest, and Inhibiting Migration of A549 Lung Cancer Cells
- in-vitro, Lung, A549 - in-vitro, Lung, H23 - in-vitro, Lung, H460
tumCV↓, selectivity↑, Apoptosis↑, ROS↑, TumCCA↑, TumCMig↓, TumCP↓, MMP↓, BAD↑, Cyt‑c↑, cl‑Casp3↑, cl‑PARP↑, Bcl-2↓, p‑ERK↓, p‑STAT3↓, NF-kB↓,
8317- LIN,    Linalool induces cell cycle arrest and apoptosis in HepG2 cells through oxidative stress generation and modulation of Ras/MAPK and Akt/mTOR pathways
- in-vitro, Liver, HepG2
TumCP↓, TumCCA↑, CDK4↓, cycA1/CCNA1↓, P21↑, p27/CDKN1B↑, Apoptosis↑, MMP↓, Casp3↑, cl‑PARP↑, DNAdam↑, RAS↓, Akt↓, mTOR↓, ROS↑, MAPK↑,
8401- LT,    Multi-Faceted Role of Luteolin in Cancer Metastasis: EMT, Angiogenesis, ECM Degradation and Apoptosis
- Review, Var, NA
EMT↓, N-cadherin↓, Vim↓, VEGF↓, VEGFR1↓, MMPs↓, Telomerase↓, NF-kB↓, cMyc↓, Bax:Bcl2↑, Casp3↑, PI3K↓, Akt↓, FOXO3↑, P21↑, p27/CDKN1B↑, cl‑PARP↑, Cyt‑c↑, NOTCH↓, HES1↓, ROS↑, SOD↓, miR-34b-5p↑, Hif1a↓, P21↓, survivin↓, Mcl-1?, Bcl-xL↓, MDM2↓, MMP2↓, MMP9↓, MMP3↓, MMP16↓, miR-384↑, NRF2↓, HO-1↓, angioG↓,
2914- LT,    Therapeutic Potential of Luteolin on Cancer
- Review, Var, NA
*antiOx↑, *IronCh↑, *toxicity↓, *BioAv↓, *BioAv↑, DNAdam↑, TumCP↓, DR5↑, P53↑, JNK↑, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, cl‑PARP↑, survivin↓, cycD1/CCND1↓, CycB/CCNB1↓, CDC2↓, P21↑, angioG↓, MMP2↓, AEG1↓, VEGF↓, VEGFR2/KDR/Flk1↓, MMP9↓, CXCR4↓, PI3K↓, Akt↓, ERK↓, TumAuto↑, LC3B-II↑, EMT↓, E-cadherin↑, N-cadherin↓, Wnt↓, ROS↑, NICD↓, p‑GSK‐3β↓, iNOS↓, COX2/PTGS2↓, NRF2↑, Ca+2↑, ChemoSen↑, ChemoSen↓, IFN-γ↓, RadioS↑, MDM2↓, NOTCH1↓, AR↓, TIMP1↑, TIMP2↑, ER Stress↑, CDK2↓, Telomerase↓, p‑NF-kB↑, p‑cMyc↑, hTERT/TERT↓, RAS↓, YAP/TEAD↓, TAZ↓, NF-kB↓, NRF2↓, HO-1↓, MDR1↓,
2919- LT,    Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence
- Review, Var, NA
RadioS↑, ChemoSen↑, chemoP↑, *lipid-P↓, *Catalase↑, *SOD↑, *GPx↑, *GSTs↑, *GSH↑, *TNF-α↓, *IL1β↓, *Casp3↓, *IL10↑, NRF2↓, HO-1↓, NQO1↓, GSH↓, MET↓, p‑MET↓, p‑Akt↓, HGF/c-Met↓, NF-kB↓, Bcl-2↓, SOD2↓, Casp8↑, Casp3↑, PARP↑, MAPK↓, NLRP3↓, ASC↓, Casp1↓, IL6↓, IKKα↓, p‑p65↓, p‑p38↑, MMP2↓, ICAM-1↓, EGFR↑, p‑PI3K↓, E-cadherin↓, ZO-1↑, N-cadherin↓, CLDN1↓, β-catenin/ZEB1↓, Snail↓, Vim↑, ITGB1↓, FAK↓, p‑Src↓, Rac1↓, Cdc42↓, Rho↓, PCNA↓, Tyro3↓, AXL↓, CEA↓, NSE↓, SOD↓, Catalase↓, GPx↓, GSR↓, GSTs↓, GSH↓, VitE↓, VitC↓, CYP1A1↓, cFos↑, AR↓, AIF↑, p‑STAT6↓, p‑MDM2↓, NOTCH1↓, VEGF↓, H3↓, H4↓, HDAC↓, SIRT1↓, ROS↑, DR5↑, Cyt‑c↑, p‑JNK↑, PTEN↓, mTOR↓, CD34↓, FasL↑, Fas↑, XIAP↓, p‑eIF2α↑, CHOP/DDIT3↑, LC3II↑, PD-1↓, STAT3↓, IL2↑, EMT↓, cachexia↓, BioAv↑, *Half-Life↝, *eff↑,
8345- Lut,    Lutein inhibits breast cancer cell growth by suppressing antioxidant and cell survival signals and induces apoptosis
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
tumCV↓, SOD2↓, HO-1↓, NRF2↓, p‑Akt↓, p‑ERK↓, NF-kB↓, Apoptosis↑, Casp3↑, Bcl-2↓, PARP↓, ROS↓, XBP-1↓, Dose↝, Risk↓, MMP↓, selectivity↑, p‑Akt↓,
3277- Lyco,    Recent trends and advances in the epidemiology, synergism, and delivery system of lycopene as an anti-cancer agent
- Review, Var, NA
antiOx↑, TumCP↓, Apoptosis↑, TumMeta↑, ChemoSen↑, BioAv↓, Dose↝, BioAv↓, BioAv↑, SOD↑, Catalase↑, GPx↑, IL2↑, IL4↑, IL1↑, TNF-α↑, GSH↑, GPx↑, GSTA1↑, GSR↑, PPARγ↑, Casp3↑, NF-kB↓, COX2/PTGS2↓, Bcl-2↑, BAX↓, P53↓, CHK1↓, Chk2↓, γH2AX↓, DNAdam↓, ROS↓, P21↑, PCNA↓, β-catenin/ZEB1↓, PGE2↓, ERK↓, cMyc↓, cycE/CCNE↓, JAK1↓, STAT3↓, SIRT1↑, cl‑PARP↑, cycD1/CCND1↓, TNF-α↓, IL6↓, p65↓, MMP2↓, MMP9↓, Wnt↓,
8420- Lyco,    Anticancer activity of lycopene in HT-29 colon cancer cell line
- in-vitro, CRC, HT-29
Risk↓, Dose↝, TumCP↓, Casp3↑, BAX↑, cl‑PARP↑, 8-oxo-dG↑, γH2AX↑, Cyt‑c↑,
4786- Lyco,    Anti-proliferative and apoptosis-inducing activity of lycopene against three subtypes of human breast cancer cell lines
- in-vitro, BC, MDA-MB-468 - in-vitro, BC, MCF7 - in-vitro, BC, SkBr3
TumCP↓, TumCCA↑, cl‑PARP↑, ERK↑, cycD1/CCND1↓, P21↓, p‑Akt↓, mTOR↓, BAX↑, AntiCan↑, Risk↓,
2533- M-Blu,  PDT,    Methylene blue-mediated photodynamic therapy enhances apoptosis in lung cancer cells
- in-vitro, Lung, A549
MMP↓, p‑MAPK↑, ROS↑, cl‑PARP↑, Bcl-2↓, Mcl-1↓, eff↓,
8525- MAG,    Mechanisms for the magnolol-induced cell death of CGTH W-2 thyroid carcinoma cells
- in-vitro, Thyroid, NA
Casp3↑, Casp7↑, PARP↑, Akt↓, p‑PTEN↓, p‑Akt↓,
8524- MAG,    Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells
- in-vitro, Pca, PC3 - in-vitro, CRC, HCT116
Apoptosis↑, Akt?, BAD↑, Cyt‑c↑, cl‑Casp8↑, cl‑Casp9↑, cl‑Casp3↑, cl‑PARP↑, NA⇅, selectivity↑, p‑EGFR↓, p‑PI3K↓, p‑Akt↓,
8523- MAG,    Anticancer potential of magnolol for lung cancer treatment
- in-vitro, Lung, A549
TumCG↓, LDH↑, TumCCA↑, Casp3↑, cl‑PARP↑, NF-kB↓,
8521- MAG,    Magnolol induces apoptosis via caspase-independent pathways in non-small cell lung cancer cells
- in-vitro, Lung, A549 - in-vitro, Lung, H520 - in-vitro, Lung, NCI-H441
TumCP↓, DNAdam↑, MMP↓, selectivity↑, BID↑, BAX↑, Cyt‑c↑, AIF↑, Endon↑, cl‑PARP↑, PI3K↓, Akt↓, ERK↓, p38↑, JNK↑,
8519- MAG,    Magnolol inhibits growth of gallbladder cancer cells through the p53 pathway
- vitro+vivo, Gall, NA
TumCG?, TumCCA↑, mt-Apoptosis↑, P53↑, P21↑, cycD1/CCND1↓, CDC25↓, CDK2↓, MMP↓, Bax:Bcl2↑, Casp9↑, Casp3↑, cl‑PARP↑,
4537- MAG,    Effects of magnolol on UVB-induced skin cancer development in mice and its possible mechanism of action
- in-vivo, Melanoma, NA - in-vitro, Melanoma, A431
*cl‑Casp8↑, *PARP↑, *P21↑, tumCV↓, TumCP↓, TumCCA↑, CycB/CCNB1↓, cycA1/CCNA1↓, CDK4↓, CDC2↓, P21↑, Apoptosis↑,
4531- MAG,    Magnolol-induced apoptosis in HCT-116 colon cancer cells is associated with the AMP-activated protein kinase signaling pathway
- in-vitro, CRC, HCT116
Apoptosis↑, DNAdam↑, Casp3↑, cl‑PARP↑, p‑AMPK↑, Bcl-2↓, P53↑, BAX↑, Cyt‑c↑, TumCMig↓, TumCI↓,
8555- Matr,    Matrine Exerts Pharmacological Effects Through Multiple Signaling Pathways: A Comprehensive Review
- Review, Var, NA
*AntiTum↑, *Inflam↓, *Analgesic↑, *AntiViral↑, *Imm↑, *PI3K↑, *Akt↑, *mTOR↑, TumAuto↑, PI3K↓, Akt↓, mTOR↓, Beclin-1/ATG6↑, E-cadherin↑, Vim↓, MMP2↓, MMP9↓, Snail↓, Slug↓, PTEN↑, TumCP↓, TumCMig↓, TumCI↓, ChemoSen↑, ROS↑, uPA↓, p‑ERK↓, cachexia↓, antiD↑, GSK‐3β↓, LC3B-II↑, p62↓, Apoptosis↑, Casp3↑, Casp8↑, Casp9↑, FOXO1↑, FOXO3↑, FOXO4↑, PARP↑, BIM↑, Bcl-2↓, survivin↓, miR-21↓, *HOTAIR↑, *p‑Akt↑, *p‑STAT3↑, *STAT3↑, *ROS↓, Wnt↓, β-catenin/ZEB1↓, NOTCH1↓, JAG1↓, HES1↓, BioAv↝, toxicity↝,
8635- MBZ,    The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma
- vitro+vivo, Melanoma, NA
TumCCA↑, cMyc↓, cl‑Casp3↑, cl‑PARP↑, eff↑, TumCP↓, BRAF↓, OS↑, TumCG↓, p‑MEK↓, p‑ERK↓,
8641- MBZ,  ONC201,    The therapeutic potential of repurposed mebendazole, alone and in synergistic combination with ONC201, in the treatment of diffuse midline glioma
- in-vitro, GBM, NA
TumCCA↑, P21↑, p27/CDKN1B↑, Apoptosis↑, Casp3↑, cl‑PARP↑, Synergy↑, ChemoSen↑,
8648- MBZ,    Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature
- Review, Var, NA
angioG↓, MMPs↓, MDR1↓, TubPol↓, RadioS?, ChemoSen?, TumCG↓, TumMeta?, OS↑, BioAv↓, BioAv↑, BBB↑, mitA↑, HH↓, Shh↓, Synergy↑, Gli1↓, PTCH2↓, XIAP↓, cl‑PARP↑, Casp3↑, BRAF↓, MEK↓, SYN1↑, Cyt‑c↑, TumVol↓, VEGFR2/KDR/Flk1↓, VEGF↓, VCAM-1↓, DYRK1B↓, QoL↑, Dose↝,
8822- MCP,    Modified citrus pectin inhibited bladder tumor growth through downregulation of galectin-3
- vitro+vivo, CRC, T24/HTB-9 - in-vitro, Bladder, J82
TumCCA↑, cycD1/CCND1↓, p‑cDC2↓, Casp3↑, cl‑Casp3↑, cl‑PARP↑, Gal-3↓, Akt↓, TumCG↓, Ki-67↓, Dose⇅,
8756- MeSA,    THE MAIN CYTOTOXIC EFFECTS OF METHYLSELENINIC ACID ON VARIOUS CANCER CELLS
- Review, Var, NA
ROS↑, GSH↓, RadioS↑, angioG↓, p‑Akt↓, IκB↓, NF-kB↓, ITGB3↓, p‑FOXO3↓, BAX↑, Cyt‑c↑, proCasp3↑, PARP↑, Glycolysis↓, TCA↓, NRF2↑, DNMT1↓, Hif1a↓, ER Stress↑, ChemoSen↑,
8742- MeSA,    Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells
- in-vitro, Pca, DU145
TumCCA↑, DNAdam↑, Casp↑, cl‑PARP↑, p27/CDKN1B↑, P21↑, Apoptosis↑, Akt↓, ERK↓,
2375- MET,    Metformin inhibits gastric cancer via the inhibition of HIF1α/PKM2 signaling
- in-vitro, GC, SGC-7901
tumCV↓, TumCI↓, TumCMig↓, Apoptosis↑, PARP↓, PI3K↓, Akt↓, Hif1a↓, PKM2↓, COX2/PTGS2↓,
2374- MET,    Metformin Induces Apoptosis and Downregulates Pyruvate Kinase M2 in Breast Cancer Cells Only When Grown in Nutrient-Poor Conditions
- in-vitro, BC, MCF7 - in-vitro, BC, SkBr3 - in-vitro, BC, MDA-MB-231
eff↑, Apoptosis↑, Glycolysis↓, PKM2↓, mTOR↓, PARP↓,
3486- MF,    Pulsed electromagnetic field potentiates etoposide-induced MCF-7 cell death
- in-vitro, BC, MCF-10AT
ChemoSen↑, tumCV↓, cl‑PARP↑, Casp7↑, Casp9↑, survivin↓, BAX↑, DNAdam↑, ROS↑, eff↓,
4353- MF,  Chemo,    Pulsed Electromagnetic Field Enhances Doxorubicin-induced Reduction in the Viability of MCF-7 Breast Cancer Cells
- in-vitro, BC, MCF7
TumCCA↑, Apoptosis↑, ChemoSen↑, TumCCA↑, Casp↝, p‑CDK2↓, cycE/CCNE↓, Fas↑, BAX↑, survivin↓, Mcl-1↓, cl‑PARP↑, cl‑Casp7↑, cl‑Casp8↑, cl‑Casp9↑,
496- MF,    Low-Frequency Magnetic Fields (LF-MFs) Inhibit Proliferation by Triggering Apoptosis and Altering Cell Cycle Distribution in Breast Cancer Cells
- in-vitro, BC, MCF7 - in-vitro, BC, ZR-75-1 - in-vitro, BC, T47D - in-vitro, BC, MDA-MB-231
ROS↑, PI3K↓, Akt↓, GSK‐3β↑, Apoptosis↑, cl‑PARP↑, cl‑Casp3↑, BAX↑, Bcl-2↓, CycB/CCNB1↓, TumCCA↑, p‑Akt↓, TumCP↓, selectivity↑, eff↓,
8898- MOR,    Molecular mechanism of anti-cancerous potential of Morin extracted from mulberry in Hela cells
- in-vitro, Cerv, HeLa
TumCP↓, TumCCA↑, Apoptosis↑, P53↑, P21↑, WEE1↑, CDK1↓, CDC25↓, survivin↓, CycB/CCNB1↓, Chk2↓, BAX↑, BAD↑, Cyt‑c↑, APAF1↑, Casp9↑, TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1↑, DR5↑, FasL↑, FADD↑, Casp10↑, PARP↑, PI3K↑, Akt↑, mTOR↑, p70S6↑, Diablo↑, Bcl-2↓, Bcl-xL↓, AMPK↓, IAP1↓, NF-kB↓, ROS↑,
8863- MOR,    Morin Inhibits Proliferation of SW480 Colorectal Cancer Cells by Inducing Apoptosis Mediated by Reactive Oxygen Species Formation and Uncoupling of Warburg Effect
- in-vitro, Colon, SW48
TumCP↓, Apoptosis↑, ROS↑, MMP↓, cl‑PARP↑, cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, BAX↑, Bcl-2↓, ATP↓, GlucoseCon↓, GLUT1↓, Warburg↓, Dose↝, Catalase↓, GSH↓, ADP:ATP↑, AMP↑,
8892- MOR,  Cisplatin,    Morin Hydrate Reverses Cisplatin Resistance by Impairing PARP1/HMGB1-Dependent Autophagy in Hepatocellular Carcinoma
- vitro+vivo, HCC, NA
PARP↓, HMGB1↓, ChemoSen↑,
8886- MOR,  doxoR,    Morin overcomes doxorubicin resistance in human breast cancer by inducing DNA damage and modulating the LKB1/AMPK/mTORC1 signaling pathway
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF7
DNAdam↑, DNArepair↓, TumCCA↑, cycD1/CCND1↓, CDK4↓, cycE/CCNE↓, CycB/CCNB1↓, PARP↓, Bcl-xL↓, p‑AMPK↑, p‑STK11/LKB1↑, p‑mTOR↓, p‑Akt↓, p‑GSK‐3β↓, tumCV↓,

Showing Research Papers: 301 to 350 of 460
Prev Page 7 of 10 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 460

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

NA↓, 2,   NA↑, 2,   NA⇅, 1,   NA?, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 2,   antiOx↑, 2,   ARE/EpRE↑, 1,   Catalase↓, 5,   Catalase↑, 2,   Copper↑, 1,   ENOX2↓, 1,   Fenton↑, 3,   GPx↓, 3,   GPx↑, 2,   GPx1↓, 1,   GPx4↓, 3,   GSH↓, 30,   GSH↑, 5,   i-GSH∅, 1,   GSH/GSSG↓, 2,   GSR↓, 2,   GSR↑, 2,   GSSG↑, 2,   GSTs↓, 2,   GSTs↑, 2,   H2O2↑, 5,   i-H2O2↑, 1,   HO-1↓, 10,   HO-1↑, 11,   HO-2↓, 1,   Iron↑, 2,   i-Iron↑, 1,   Keap1↓, 2,   lipid-P?, 1,   lipid-P↓, 1,   lipid-P↑, 10,   MDA↓, 2,   MDA↑, 4,   MPO↓, 1,   NOX4↑, 1,   NQO1↓, 3,   NQO1↑, 1,   NRF2↓, 18,   NRF2↑, 18,   p‑NRF2↑, 1,   Prx↓, 1,   Prx4↑, 1,   PrxII↓, 1,   RNS↑, 2,   ROS?, 3,   ROS↓, 20,   ROS↑, 231,   ROS⇅, 10,   ROS↝, 1,   ROS∅, 2,   i-ROS↑, 2,   mt-ROS↑, 7,   SOD↓, 6,   SOD↑, 4,   SOD1↓, 1,   SOD1↑, 1,   SOD2↓, 4,   SOD2↑, 1,   TAC↑, 2,   Thiols↓, 1,   Trx↓, 2,   ox-Trx1↑, 1,   TrxR↓, 7,   TrxR1↓, 6,   VitC↓, 1,   VitE↓, 1,   xCT/SLC7A11↓, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

Ferritin↓, 1,   IronCh↑, 1,   Tf↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ADP:ATP↑, 1,   CDC2↓, 7,   CDC25↓, 15,   EGF↓, 4,   ETC↓, 3,   MFN2↑, 1,   mitResp↓, 2,   MKK7↓, 1,   mtDam↑, 20,   OCR↓, 3,   OCR↑, 1,   OXPHOS↓, 5,   mt-OXPHOS↓, 2,   PDH↓, 2,   PDH↝, 1,   p‑PDH↑, 1,   PINK1↑, 3,   SDH↓, 1,   SIRT3↓, 1,   SIRT3↑, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

12LOX↓, 1,   5LO↓, 1,   ACC↑, 3,   p‑ACC↑, 2,   ALAT↓, 4,   ALDOA↓, 2,   AMP↑, 1,   AMPK↓, 2,   AMPK↑, 22,   p‑AMPK↑, 2,   p‑AMT/GCST/T-protein↑, 1,   ATP↓, 15,   ATP↑, 1,   citrate↓, 1,   CPT1A↓, 1,   ECAR↝, 1,   ENO1↓, 3,   FASN↓, 4,   FASN↑, 1,   FBPase↑, 1,   GAPDH↓, 2,   glucoNG↓, 1,   glucoNG↑, 1,   glucose↓, 2,   GlucoseCon↓, 8,   GlutMet↓, 1,   Glycolysis↓, 23,   GSK‐3β↓, 9,   GSK‐3β↑, 5,   p‑GSK‐3β↓, 8,   H2S↑, 1,   HK1↓, 1,   HK2↓, 13,   HMG-CoA↓, 1,   lactateProd↓, 12,   LDHA↓, 6,   LDL↓, 2,   lipidLev↓, 1,   MCT4↓, 1,   NAD↓, 2,   NADPH↓, 1,   NADPH↑, 2,   O-Glc↓, 1,   PCK1↓, 1,   PDK1 / PDPK1?, 2,   PDK1 / PDPK1↓, 8,   PDKs↓, 1,   PFK↓, 3,   PFK2?, 1,   PGK1↓, 1,   PKM2↓, 13,   PKM2∅, 1,   PLA2↓, 1,   PPP↓, 1,   SIRT1↓, 9,   SIRT1↑, 2,   TCA↓, 3,   TS↓, 1,   Warburg↓, 5,   β-oxidation↓, 2,  

Cell Death(tgid=5) ⓘ

14-3-3 proteins↓, 1,   AIF↑, 13,   APAF1↑, 11,   Apoptosis↓, 9,   Apoptosis↑, 253,   mt-Apoptosis↑, 2,   ASC↓, 1,   BAD↓, 3,   BAD↑, 21,   p‑BAD↓, 2,   Bak↓, 1,   Bak↑, 14,   BAX↓, 4,   BAX↑, 146,   BAX↝, 1,   BAX∅, 1,   Bax:Bcl2↑, 44,   Bcl-2↓, 167,   Bcl-2↑, 6,   Bcl-2↝, 1,   Bcl-2∅, 2,   cl‑Bcl-2↓, 1,   cl‑Bcl-2↑, 1,   Bcl-xL↓, 53,   Bcl-xL↑, 1,   Bcl-xL∅, 1,   BID↑, 11,   cl‑BID↑, 2,   BIM↑, 10,   Casp↑, 38,   Casp↝, 2,   cl‑Casp↑, 2,   Casp1↓, 1,   Casp1↑, 2,   Casp10↑, 3,   Casp12?, 1,   Casp12↑, 3,   Casp2↑, 1,   Casp3?, 1,   Casp3↓, 3,   Casp3↑, 215,   Casp3↝, 1,   Casp3∅, 1,   cl‑Casp3↓, 1,   cl‑Casp3↑, 94,   cl‑Casp3⇅, 1,   cl‑Casp3∅, 1,   proCasp3↓, 4,   proCasp3↑, 5,   Casp6↓, 1,   Casp6↑, 3,   Casp7↑, 29,   cl‑Casp7↑, 11,   Casp8↓, 2,   Casp8↑, 60,   Casp8∅, 2,   cl‑Casp8↑, 24,   proCasp8↓, 1,   proCasp8↑, 4,   Casp9?, 1,   Casp9↓, 2,   Casp9↑, 127,   Casp9∅, 1,   cl‑Casp9↓, 1,   cl‑Casp9↑, 38,   proCasp9↓, 1,   proCasp9↑, 4,   cFLIP↓, 8,   Cyt‑c↓, 3,   Cyt‑c↑, 126,   Cyt‑c↝, 2,   Cyt‑c?, 1,   Diablo↑, 12,   DR5↑, 30,   Endon↑, 1,   FADD↑, 9,   Fas↓, 1,   Fas↑, 21,   FasL↑, 10,   Ferroptosis↓, 1,   Ferroptosis↑, 5,   GRP58↓, 1,   GSDME↑, 1,   cl‑GSDME↑, 1,   HEY1↓, 2,   IAP1↓, 11,   IAP2/BIRC3↓, 5,   IAP2/BIRC3↑, 1,   cl‑IAP2/BIRC3↑, 1,   ICAD↓, 2,   ICD↑, 1,   iNOS↓, 12,   Mcl-1?, 1,   Mcl-1↓, 35,   Mcl-1↑, 1,   cl‑Mcl-1↑, 1,   MDM2↓, 11,   MDM2↑, 1,   p‑MDM2↓, 2,   MLKL↑, 2,   p‑MLKL↓, 1,   MOMP↓, 1,   MOMP↑, 1,   Necroptosis↑, 4,   necrosis↑, 7,   NOXA↑, 5,   p38↓, 2,   p38↑, 18,   p‑p38↓, 4,   p‑p38↑, 10,   PDCD4↑, 1,   PUMA↑, 10,   Pyro↑, 4,   RIP1↓, 2,   RIP3↓, 1,   RIP3↑, 2,   p‑RIP3↑, 2,   survivin↓, 73,   TNFR 1↑, 2,   TRAIL↑, 3,   TRAILR↑, 2,   TumCD↓, 1,   TumCD↑, 23,   XIAP?, 1,   XIAP↓, 35,   XIAP↑, 1,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt?, 1,   Akt↓, 118,   Akt↑, 4,   p‑Akt↓, 49,   AKT1↓, 1,   BRAF↓, 2,   CaMKII ↓, 2,   CIP2A↓, 1,   CK2↓, 4,   cMET↓, 1,   p‑cMET↑, 1,   p‑CREB↓, 1,   cSrc↓, 6,   DYRK1B↓, 1,   EF-1α↓, 1,   EGFR↓, 29,   EGFR↑, 2,   p‑EGFR↓, 1,   ERK↓, 36,   ERK↑, 12,   p‑ERK↓, 21,   p‑ERK↑, 5,   FGFR1↓, 3,   FGFR2↓, 1,   HER2/EBBR2↓, 14,   HGF/c-Met↓, 3,   IGF-1R↓, 4,   IGF-1R↑, 1,   IGFR↓, 2,   IKKα↓, 7,   IKKα↑, 1,   ILK↓, 1,   IκB↓, 3,   IκB↑, 1,   p‑IκB↓, 1,   JAK↓, 2,   JAK1?, 1,   JAK1↓, 8,   JAK1↑, 1,   p‑JAK1↓, 2,   JAK2↓, 10,   p‑JAK2↓, 5,   JNK↓, 2,   JNK↑, 23,   p‑JNK↓, 2,   p‑JNK↑, 10,   cl‑JNK↑, 1,   MAPK↓, 29,   MAPK↑, 10,   MAPK↝, 1,   p‑MAPK↓, 1,   p‑MAPK↑, 1,   MEK↓, 4,   p‑MEK↓, 1,   p‑MEK↑, 1,   MKK4↓, 1,   mTOR↓, 56,   mTOR↑, 4,   mTOR↝, 1,   p‑mTOR↓, 13,   mTORC2↓, 4,   p70S6↓, 2,   p70S6↑, 1,   P70S6K↓, 3,   p‑P70S6K↓, 2,   PDGFR-BB↓, 1,   p‑PDGFR-BB↓, 1,   PI3K↓, 84,   PI3K↑, 1,   p‑PI3K↓, 8,   PI3K/Akt↓, 3,   PI3k/Akt/mTOR↓, 1,   PIAS-3↑, 1,   PKA↓, 1,   PKCδ↓, 8,   cl‑PKCδ↑, 1,   PP2A↑, 1,   PRAS40↑, 1,   PTEN↓, 2,   PTEN↑, 21,   p‑PTEN↓, 1,   Raf↓, 4,   c-Raf↓, 1,   RAS↓, 11,   RSK2/RPS6KA3/p90RSK2↓, 1,   RTK-RAS↓, 1,   SHP1↑, 4,   Sp1/3/4↓, 7,   Src↓, 3,   p‑Src↓, 1,   STAT↓, 2,   p‑STAT↓, 1,   STAT3↓, 58,   STAT3↑, 2,   p‑STAT3↓, 18,   p‑STAT3↑, 1,   STAT5↓, 2,   STAT6↓, 2,   p‑STAT6↓, 1,   STK11/LKB1↑, 1,   p‑STK11/LKB1↑, 2,   THEM4/CTMP↑, 1,   TK1↓, 1,   TSC2↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

ATF1↓, 1,   ATF2↓, 1,   ATF3↑, 2,   ATF4↓, 1,   ATF4↑, 15,   ATF4↝, 1,   CBP↓, 1,   cJun↓, 6,   cJun↑, 4,   cMyc↓, 35,   cMyc↑, 1,   p‑cMyc↑, 1,   DNMT1↓, 7,   DNMT3A↓, 2,   DNMTs↓, 3,   EZH2↓, 2,   FOXM1↓, 3,   FOXO1↑, 2,   FOXO3↓, 3,   FOXO3↑, 4,   FOXO3↝, 1,   p‑FOXO3↓, 1,   FOXO4↑, 2,   H3↓, 4,   H3↑, 2,   p‑H3↓, 2,   ac‑H3↑, 1,   H4↓, 1,   H4↑, 1,   ac‑H4↑, 1,   HATs↓, 4,   HATs↑, 1,   HDAC↓, 16,   HDAC1↓, 4,   HDAC2↓, 4,   HDAC3↓, 3,   HDAC8↓, 1,   HES1↓, 2,   miR-134↑, 1,   miR-139-5p↑, 1,   miR-200b↑, 1,   miR-205↑, 1,   miR-21↓, 5,   miR-21↑, 1,   miR-21↝, 1,   miR-25-5p↓, 1,   miR-27a-3p↓, 1,   miR-29b↓, 1,   miR-339-5p↝, 1,   miR-340↑, 1,   miR-34a↑, 1,   miR-34b-5p↑, 1,   miR-384↑, 1,   Myc↓, 4,   MYCN↓, 1,   OCT4↓, 6,   other↓, 1,   other↑, 1,   other⇅, 1,   other↝, 7,   PhotoS↑, 1,   SOX2↓, 3,   SOX4↓, 1,   SOX4↑, 1,   SOX9↓, 1,   SUV39H↓, 2,   TCF-4↓, 1,   TFAP2A↓, 1,   tumCV↓, 76,   tumCV∅, 1,   ZBTB10↑, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

ATF6↑, 3,   CHOP/DDIT3↑, 36,   cl‑CHOP/DDIT3↑, 1,   eIF2α↓, 1,   eIF2α↑, 6,   p‑eIF2α↑, 9,   ER Stress↓, 1,   ER Stress↑, 53,   GRP78/BiP↓, 1,   GRP78/BiP↑, 18,   HSF1↓, 1,   HSP27↓, 5,   HSP27↑, 1,   HSP27↝, 1,   HSP70/HSPA5↓, 9,   HSP70/HSPA5↑, 2,   HSP70/HSPA5↝, 1,   HSP72↓, 1,   HSP90↓, 11,   HSPs↓, 1,   IRE1↑, 6,   PDI↑, 1,   PERK↑, 9,   Proteasome↓, 1,   SERPINH1/HSP47↓, 1,   UPR↑, 11,   XBP-1↓, 2,   XBP-1↑, 4,   XBP-1↝, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG13↑, 1,   ATG16L1↑, 1,   ATG3↓, 1,   ATG3↑, 4,   ATG5↑, 12,   ATG7↑, 3,   Beclin-1/ATG6↓, 2,   Beclin-1/ATG6↑, 20,   CTSB↓, 1,   CTSD↓, 1,   LC3‑Ⅱ/LC3‑Ⅰ↓, 1,   LC3‑Ⅱ/LC3‑Ⅰ↑, 6,   LC3A↑, 1,   LC3B↑, 2,   LC3B-II↑, 5,   LC3I↓, 1,   LC3I↑, 1,   LC3II↓, 1,   LC3II↑, 14,   LC3s↑, 1,   lysoMP↑, 1,   MitoP↑, 1,   p62↓, 10,   p62↑, 5,   PARK2↑, 3,   RUBCN↓, 1,   SESN2↑, 1,   TumAuto↑, 44,   TumAuto⇅, 1,   ULK1/ATG1↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

8-oxo-dG↑, 1,   ATM↑, 1,   p‑ATM↑, 1,   BRCA1↓, 1,   BRCA2↓, 1,   DFF45↓, 2,   DFF45↑, 3,   DNA-PK↑, 1,   DNAdam↓, 4,   DNAdam↑, 71,   DNArepair↓, 4,   ERCC1↓, 1,   ERCC4/XPF↓, 1,   hTERT/TERT↓, 7,   Ku70/XRCC6↓, 1,   MGMT↓, 1,   p16↑, 1,   P53?, 1,   P53↓, 6,   P53↑, 81,   p‑P53↓, 1,   p‑P53↑, 7,   ac‑P53↑, 1,   p53 Wildtype↓, 1,   PARP↓, 22,   PARP↑, 85,   PARP↝, 4,   PARP∅, 1,   p‑PARP↑, 6,   cl‑PARP↓, 6,   cl‑PARP↑, 324,   cl‑PARP↝, 1,   cl‑PARP∅, 2,   proPARP↓, 1,   PCNA↓, 21,   SIRT6↑, 1,   Telomerase↓, 13,   TOP1↓, 4,   TOP2↓, 3,   TOP2↑, 1,   TP53↓, 1,   TP53↑, 1,   TRF2↓, 1,   γH2AX↓, 1,   γH2AX↑, 12,   p‑γH2AX↑, 2,  

Cell Cycle & Senescence(tgid=11) ⓘ

CC(CDKs/cyclins)↓, 1,   CDK1↓, 20,   CDK1↑, 1,   p‑CDK1↓, 2,   p‑CDK1↑, 1,   CDK1/2/5/9↓, 1,   CDK2↓, 38,   CDK2↑, 3,   p‑CDK2↓, 2,   CDK4↓, 42,   CDK4↑, 1,   CDK4/6↓, 1,   CDK6↓, 21,   CDK6↑, 2,   CDK8↓, 1,   CHK1↓, 2,   CHK1↑, 1,   Chk2↓, 3,   Chk2↑, 1,   ChrCon↑, 1,   Cyc↓, 2,   cycA1/CCNA1↓, 14,   CycB/CCNB1↓, 31,   CycB/CCNB1↑, 6,   cycD1/CCND1↓, 82,   cycD1/CCND1↑, 1,   cycD1/CCND1↝, 1,   CycD3↓, 4,   CycD3↑, 1,   cycE/CCNE↓, 26,   cycE/CCNE↑, 1,   E2Fs↓, 2,   GADD45A↓, 1,   GADD45A↑, 1,   Ki-67↓, 21,   MAD↓, 1,   mitA↑, 3,   p19↑, 1,   P21?, 2,   P21↓, 6,   P21↑, 61,   P21↝, 1,   p27/CDKN1B↓, 3,   p27/CDKN1B↑, 28,   pRB↑, 1,   p‑pRB↓, 2,   p‑RB1↓, 7,   cl‑RB1↓, 1,   Securin↓, 1,   TubPol↓, 1,   TumCCA?, 1,   TumCCA↓, 7,   TumCCA↑, 188,   WEE1↑, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

4E-BP1↓, 1,   p‑4E-BP1↓, 1,   ALDH↓, 4,   Axin2↑, 1,   BMI1↓, 1,   CD133↓, 2,   CD24↓, 2,   CD34↓, 1,   cFos↓, 6,   cFos↑, 1,   cMYB↓, 1,   CSCs↓, 21,   Diff↓, 1,   Diff↑, 1,   FGF↓, 5,   Gli↓, 1,   Gli1↓, 5,   HH↓, 6,   HMGCR↓, 1,   IGF-1↓, 8,   IGF-2↓, 1,   IGFBP1↑, 1,   IGFBP3↑, 3,   JAG1↓, 1,   Ki-67↓, 21,   Let-7↑, 1,   mTORC1↓, 4,   Nanog↓, 3,   Nestin↓, 1,   NICD↓, 1,   NOTCH↓, 10,   NOTCH↑, 1,   NOTCH1↓, 10,   NOTCH1↑, 1,   NOTCH2↑, 1,   NOTCH3↓, 3,   OGFr↑, 1,   p300↓, 1,   PTCH2↓, 1,   SAL↑, 1,   SCF↓, 2,   Shh↓, 7,   Smo↓, 2,   STAT1↓, 1,   Sufu↑, 1,   TAZ↓, 1,   TumCG?, 1,   TumCG↓, 72,   TumCG↑, 3,   TumCP↓, 131,   TumCP↑, 6,   tyrosinase↓, 2,   URGCP/URG4↓, 1,   Wnt↓, 23,   Wnt↑, 1,   Wnt/(β-catenin)↓, 3,  

Migration(tgid=13) ⓘ

AEG1↓, 1,   AntiAg↑, 1,   AP-1↓, 5,   AP-1↝, 1,   AXL↓, 3,   BACH1↓, 1,   Ca+2↓, 2,   Ca+2↑, 27,   Ca+2↝, 2,   i-Ca+2↑, 1,   CAFs/TAFs↓, 2,   cal2↓, 1,   cal2↑, 1,   Cav1↓, 1,   Cdc42↓, 2,   COL1↓, 1,   COL3A1↓, 1,   E-cadherin↓, 6,   E-cadherin↑, 28,   EM↑, 1,   EMT↓, 39,   EMT↑, 1,   EMT↝, 1,   EpCAM↓, 3,   F-actin↓, 1,   FAK↓, 8,   p‑FAK↓, 3,   Fibronectin↓, 3,   GLI2↓, 3,   IQGAP3↓, 1,   ITGA5↓, 1,   ITGB1↓, 1,   ITGB3↓, 1,   ITGB4↓, 1,   KRAS↓, 2,   LAMs↓, 1,   LEF1↓, 1,   MET↓, 3,   p‑MET↓, 1,   MMP-10↓, 2,   MMP1↓, 7,   MMP13↓, 1,   MMP16↓, 1,   MMP2↓, 60,   MMP3↓, 7,   MMP7↓, 6,   MMP9↓, 67,   MMPs↓, 24,   MMPs↝, 1,   MUC4↓, 1,   N-cadherin↓, 21,   p44↓, 1,   PAK1↓, 2,   pax↓, 1,   p‑pax↓, 1,   PDGF↓, 5,   Rac1↓, 4,   RECK↑, 1,   Rho↓, 4,   ROCK1↓, 2,   Slug↓, 8,   Smad1↓, 1,   p‑SMAD2↓, 1,   SMAD3↓, 3,   SMAD3↑, 1,   p‑SMAD3↓, 1,   p‑SMAD4↓, 1,   Snail?, 1,   Snail↓, 22,   TET1↓, 1,   TET1↑, 2,   TGF-β↓, 10,   TGF-β↑, 1,   TIMP1↑, 10,   TIMP2↑, 10,   TIMP3↑, 1,   TRIB3↑, 1,   TSC1↑, 1,   TSP-1↑, 2,   TumCA↑, 1,   TumCI?, 1,   TumCI↓, 53,   TumCMig↓, 49,   TumMeta?, 1,   TumMeta↓, 42,   TumMeta↑, 2,   Twist↓, 14,   Tyro3↓, 1,   uPA↓, 14,   uPAR↓, 1,   Vim↓, 22,   Vim↑, 1,   Zeb1↓, 7,   Zeb1↑, 1,   ZEB2↓, 2,   α-tubulin↓, 2,   α-tubulin↑, 1,   β-catenin/ZEB1↓, 32,   β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 70,   angioG↑, 1,   CD31/PECAM-1↓, 2,   ECM/TCF↓, 1,   Endoglin↑, 3,   eNOS↓, 2,   HIF-1↓, 3,   Hif1a↓, 40,   NO↓, 1,   NO↑, 4,   VCAM-1↓, 2,   VEGF↓, 79,   VEGF↑, 1,   VEGF↝, 1,   VEGFR1↓, 2,   VEGFR2/KDR/Flk1↓, 16,   p‑VEGFR2/KDR/Flk1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 4,   BBB∅, 1,   CLDN1↓, 2,   CLDN1↑, 1,   CLDN2↓, 1,   EPR↑, 1,   GLUT1↓, 9,   GLUT1↑, 1,   GLUT2↓, 1,   GLUT4↓, 1,   IBI↑, 1,   MMP↓, 135,   MMP↑, 2,   MMP∅, 1,   MPT↑, 8,   NHE1↓, 1,   OCLN↑, 1,   SVCT-2↓, 1,   SVCT-2∅, 1,   TJ↑, 1,   TRPM7↓, 1,   TRPV1↑, 2,   ZO-1↑, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CB2 / CNR2↑, 1,   CD25+↑, 1,   CD4+↑, 1,   CD44↓, 9,   cDC2↓, 4,   p‑cDC2↓, 2,   COX1↓, 1,   COX2/PTGS2↓, 61,   COX2/PTGS2↑, 2,   COX2/PTGS2↝, 1,   CXCR2↓, 1,   CXCR4↓, 10,   CXCR4↑, 1,   DR4↑, 9,   DR4∅, 1,   FOXP3↑, 1,   Gal-3↓, 1,   HMGB1↓, 2,   ICAM-1↓, 2,   IFN-γ↓, 2,   IFN-γ↑, 1,   IL1↓, 1,   IL1↑, 1,   IL10↓, 2,   IL12↓, 1,   IL1α↓, 1,   IL1β↓, 10,   IL2↑, 3,   IL4↓, 1,   IL4↑, 1,   IL6↓, 27,   IL8↓, 4,   Imm↑, 4,   Imm↝, 2,   Inflam↓, 21,   LTA/TNF-β↑, 1,   M2 MC↓, 1,   MCP1/CCL2↓, 1,   MCT1↓, 1,   MIP2↓, 1,   mPGES-1↓, 1,   NF-kB↓, 101,   NF-kB↑, 4,   NF-kB↝, 1,   p‑NF-kB↓, 2,   p‑NF-kB↑, 2,   NK cell↑, 1,   NLRP3↓, 1,   NLRP3↑, 1,   NOD1↓, 1,   p50↓, 1,   p65↓, 6,   p‑p65↓, 2,   ac‑p65↓, 1,   ac‑p65↑, 1,   PD-1↓, 3,   PD-1↝, 1,   PD-L1↓, 4,   PD-L1↑, 1,   PGE2↓, 14,   PSA↓, 6,   RAGE↓, 1,   SOCS-3↓, 1,   T-Cell↑, 1,   T-Cell↝, 1,   TCF↓, 1,   TCF↑, 1,   TLR4↓, 4,   TLR4↝, 1,   TNF-α↓, 26,   TNF-α↑, 4,   TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1↑, 2,  

Cellular Microenvironment(tgid=17) ⓘ

ADAM17↓, 1,   IM↓, 1,   pH↑, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↓, 1,   SYN1↑, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 15,   ER-α36↓, 2,   ERα/ESR1↓, 1,   GR↝, 1,   PPARα↓, 2,   PPARγ↓, 1,   PPARγ↑, 3,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ABC↓, 1,   ABCG2↓, 3,   BioAv↓, 27,   BioAv↑, 31,   BioAv↝, 9,   BioEnh↑, 5,   ChemoSen?, 1,   ChemoSen↓, 1,   ChemoSen↑, 101,   CompStab↓, 1,   CompStab↑, 2,   CompStab↝, 2,   CYP1A1↓, 1,   CYP1A1↑, 1,   CYP3A4↓, 2,   Dose?, 2,   Dose↓, 2,   Dose↑, 4,   Dose⇅, 1,   Dose↝, 38,   Dose∅, 10,   eff↓, 83,   eff↑, 66,   eff↝, 6,   eff∅, 1,   GSTA1↑, 1,   GSTP1/GSTπ↓, 1,   Half-Life↓, 7,   Half-Life↑, 1,   Half-Life↝, 11,   MDR1↓, 4,   MRP1/ABCC1↓, 5,   P-gp/ABCB1↓, 10,   P-gp/ABCB1↑, 1,   P450↓, 3,   RadioS?, 1,   RadioS↑, 30,   selectivity↓, 1,   selectivity↑, 93,   Synergy↑, 73,   TET2↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

AFP↓, 2,   ALAT↓, 4,   ALP↓, 2,   AR↓, 15,   ascitic↓, 1,   AST↓, 3,   BRAF↓, 2,   BRCA1↓, 1,   CEA↓, 2,   CRP↓, 1,   E6↓, 2,   E7↓, 2,   EGFR↓, 29,   EGFR↑, 2,   p‑EGFR↓, 1,   ERα/ESR1↓, 1,   EZH2↓, 2,   Ferritin↓, 1,   FOXM1↓, 3,   HER2/EBBR2↓, 14,   hTERT/TERT↓, 7,   IL6↓, 27,   KRAS↓, 2,   LDH↓, 2,   LDH↑, 4,   LDH↝, 1,   i-LDH↓, 1,   Myc↓, 4,   NSE↓, 1,   PD-L1↓, 4,   PD-L1↑, 1,   PSA↓, 6,   RAGE↓, 1,   TP53↓, 1,   TP53↑, 1,   TRIB3↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↓, 1,   AntiCan↑, 31,   antiCG↓, 1,   antiD↑, 1,   antiNeop↑, 2,   AntiTum↓, 2,   AntiTum↑, 12,   cachexia↓, 2,   cardioP↑, 5,   CardioT↑, 1,   chemoP↑, 17,   chemoPv↑, 14,   ChemoSideEff↓, 2,   hepatoP↓, 1,   hepatoP↑, 7,   neuroP↑, 5,   NP/CIPN↓, 1,   Obesity↓, 1,   OS↑, 10,   Pain↓, 2,   QoL↑, 2,   radioP↑, 3,   Remission↑, 1,   RenoP↑, 8,   Risk↓, 10,   toxicity?, 1,   toxicity↓, 12,   toxicity↑, 4,   toxicity↝, 9,   TumVol↓, 22,   TumVol↑, 1,   TumW↓, 9,   Weight↑, 1,   Weight∅, 1,   Wound Healing↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiBio↓, 1,   AntiP↑, 1,   Bacteria↓, 3,   GutMicro↑, 3,   GutMicro↝, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr?, 1,   Ingr↝, 2,  
Total Targets: 1014

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx?, 1,   antiOx↓, 3,   antiOx↑, 41,   i-antiOx↑, 1,   Catalase↑, 22,   GPx↑, 14,   GPx1↑, 1,   GSH↑, 15,   GSR↑, 2,   GSSG∅, 1,   GSTs↑, 9,   H2O2↓, 1,   HDL↑, 1,   HO-1↓, 1,   HO-1↑, 11,   Keap1↑, 1,   Keap1↝, 1,   lipid-P↓, 11,   MDA↓, 9,   MPO↓, 1,   NADH↓, 1,   NOX4↓, 1,   Nrf1↑, 1,   NRF2↓, 1,   NRF2↑, 23,   Prx↑, 1,   RNS↓, 3,   ROS↓, 44,   ROS↑, 2,   ROS∅, 4,   mt-ROS?, 1,   SOD↓, 1,   SOD↑, 21,   SOD1↑, 2,   SOD2↑, 2,   TAC↑, 2,   TBARS↓, 1,   uricA↓, 1,   VitC↑, 1,   VitE↑, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

Insulin↑, 2,   PGC-1α↑, 1,   PGC-1α↝, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

15-LOX/ALOX15↓, 1,   5LO↓, 2,   ALAT↓, 4,   AMPK↑, 2,   ATP↑, 3,   GAPDH↑, 1,   glucose↓, 4,   glucose↝, 1,   GSK‐3β↓, 2,   LDL↓, 4,   lipidLev↓, 1,   NAD↑, 1,   NADPH↑, 2,   SIRT1↑, 2,  

Cell Death(tgid=5) ⓘ

AIF↓, 1,   Apoptosis↓, 5,   Apoptosis∅, 1,   mt-Apoptosis↓, 1,   BAX↓, 5,   Bax:Bcl2↓, 1,   Bax:Bcl2↑, 2,   Bcl-2↑, 4,   Casp↓, 1,   Casp1↓, 1,   Casp12↓, 1,   Casp3?, 1,   Casp3↓, 7,   Casp3↑, 1,   Casp3∅, 1,   cl‑Casp3↓, 1,   cl‑Casp3↑, 1,   Casp8↑, 1,   cl‑Casp8↑, 2,   Casp9↓, 1,   Casp9↑, 1,   Casp9∅, 1,   cl‑Casp9↓, 1,   cl‑Casp9↑, 1,   Cyt‑c↓, 4,   Cyt‑c∅, 1,   Fas↑, 2,   iNOS↓, 9,   iNOS↑, 1,   p38↓, 3,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 1,   Akt↑, 1,   p‑Akt↑, 1,   Akt2↓, 1,   ERK↓, 1,   ERK↑, 1,   IGF-1R↓, 1,   IKKα↓, 1,   IκB?, 1,   JAK↓, 1,   JNK↓, 3,   JNK↑, 1,   p‑JNK↓, 2,   MAPK↓, 4,   MAPK↑, 1,   mTOR↓, 1,   mTOR↑, 1,   PDGFR-BB↓, 1,   PI3K↓, 2,   PI3K↑, 1,   PKCδ↓, 1,   STAT3↑, 1,   p‑STAT3↑, 1,   STAT6↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

p‑cMyc↑, 1,   HOTAIR↑, 1,   other↓, 2,   other↑, 1,   other↝, 1,   tumCV↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↓, 1,   ER Stress↓, 1,   GRP78/BiP↓, 1,   HSP70/HSPA5↑, 1,   IRE1↓, 1,   PERK↓, 1,   UPR↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↑, 1,   LC3II↑, 1,   p62↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↓, 1,   p16↓, 1,   P53↓, 3,   P53↑, 2,   PARP↓, 3,   PARP↑, 1,   PARP∅, 1,   p‑PARP↓, 1,   cl‑PARP↓, 2,   cl‑PARP↑, 2,   PARP1↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 1,   cycA1/CCNA1↓, 1,   cycE/CCNE↑, 1,   E2Fs↑, 1,   P21↓, 2,   P21↑, 3,   TumCCA↑, 3,  

Migration(tgid=13) ⓘ

AntiAg↑, 5,   AP-1↓, 1,   Ca+2?, 1,   Ca+2↓, 2,   Ca+2↝, 1,   MLC2/MYL9↝, 1,   MMP13↓, 2,   MMP2↓, 1,   MMP3↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   E-sel↓, 1,   Hif1a↓, 2,   NO↓, 5,   NO↑, 1,   VCAM-1↓, 2,   VEGF↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 5,   GastroP↑, 2,   GLUT1↓, 1,   MMP↓, 3,   MMP↑, 3,   MMP∅, 1,   MUC5AC↓, 1,   OCLN↝, 1,   SVCT-2↑, 1,   TJ↑, 1,   TRPA1↑, 1,   TRPC1↓, 1,   TRPV1↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CCL11↓, 1,   CD4+↑, 1,   CD8+↑, 1,   COX1↓, 3,   COX2/PTGS2↓, 16,   COX2/PTGS2↑, 1,   IL10↓, 2,   IL10↑, 1,   IL17↓, 1,   IL18↓, 1,   IL1β↓, 9,   IL6↓, 14,   IL6↑, 1,   IL8↓, 1,   Imm↑, 4,   Imm⇅, 1,   Inflam↓, 49,   pol-M2 MC↑, 1,   MCP1/CCL2↓, 1,   MyD88↓, 1,   NeuroI↓, 1,   NF-kB↓, 18,   NLRP3↓, 1,   PAF↓, 1,   PGE2↓, 4,   PGE2↑, 1,   PSA∅, 1,   Th1 response↓, 1,   Th2↑, 2,   TLR1↓, 1,   TLR4↓, 1,   TNF-α↓, 20,   β-HEX↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↑, 1,   AChE↓, 5,   BChE↓, 2,   BDNF↑, 2,   MAOA↓, 1,   NGF↑, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 6,   BACE/β-secretase↓, 2,   tau↓, 2,   p‑tau↓, 2,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

Estro↓, 1,   PPARα↑, 1,   PPARα↝, 1,   PPARγ↓, 1,   testos↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 16,   BioAv↑, 23,   BioAv↝, 9,   BioAv∅, 1,   BioEnh↑, 1,   CompStab↑, 1,   Dose↝, 4,   Dose∅, 1,   eff↑, 6,   GSTA1↑, 1,   Half-Life↑, 1,   Half-Life↝, 7,   Half-Life∅, 2,   P450↑, 1,   Synergy↑, 4,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 4,   ALP↓, 2,   AST↓, 5,   BG↓, 1,   BP↓, 4,   creat↓, 1,   CRP↓, 3,   hs-CRP↓, 1,   IL6↓, 14,   IL6↑, 1,   LDH↓, 4,   LDH↑, 1,   NOS2↓, 1,   PSA∅, 1,  

Functional Outcomes(tgid=23) ⓘ

Analgesic↑, 2,   AntiAge↑, 3,   antiAll↑, 14,   AntiArt↑, 7,   AntiCan↑, 8,   AntiDiabetic↑, 9,   antiPs↑, 2,   AntiTum↓, 1,   AntiTum↑, 3,   cardioP↑, 15,   chemoP↑, 7,   chemoPv↑, 2,   cognitive↑, 3,   hepatoP↓, 1,   hepatoP↑, 9,   memory↑, 3,   motorD↓, 1,   motorD↑, 1,   neuroP↓, 1,   neuroP↑, 27,   Obesity↓, 6,   Pain↓, 4,   radioP↑, 3,   RenoP↑, 1,   Stress↓, 1,   Stroke↓, 3,   toxicity↓, 24,   toxicity↑, 2,   toxicity↝, 4,   toxicity∅, 4,  

Infection & Microbiome(tgid=24) ⓘ

AntiBio↑, 9,   AntiFungal↓, 1,   AntiFungal↑, 2,   AntiP↓, 1,   AntiP↑, 2,   AntiViral↑, 10,   Bacteria↓, 12,   GutMicro↑, 9,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↑, 1,   Ingr↝, 4,  
Total Targets: 292

Scientific Paper Hit Count for: PARP, poly ADP-ribose polymerase (PARP) cleavage
16 Apigenin (mainly Parsley)
16 Curcumin
15 Fisetin
14 Quercetin
14 Thymoquinone
12 Baicalein
10 EGCG (Epigallocatechin Gallate)
10 Sulforaphane (mainly Broccoli)
8 Honokiol
8 Kaempferol
8 Licochalcone A
8 Shikonin
7 Ashwagandha(Withaferin A)
7 Berberine
7 Capsaicin
7 Emodin
7 Garcinol
7 Magnolol
6 Metformin
6 Boswellia (frankincense)
6 Carnosic acid
6 Chrysin
6 Gambogic Acid
6 isoorientin
6 lambertianic acid
6 Piperlongumine
6 Vitamin C (Ascorbic Acid)
5 doxorubicin
5 Betulinic acid
5 Eugenol
5 Licorice
5 Morin
5 Silymarin (Milk Thistle) silibinin
4 Cisplatin
4 Bufalin/Huachansu
4 α-Bisabolol / Chamomile oil
4 Carvacrol
4 chaetocin
4 Citric Acid
4 Docetaxel
4 Evodiamine
4 Formononetin
4 Fucoidan
4 Ginkgetin
4 Ivermectin
4 Nimbolide
4 Propolis -bee glue
4 Phenethyl isothiocyanate
4 Resveratrol
3 Auranofin
3 Silver-NanoParticles
3 Allicin (mainly Garlic)
3 5-fluorouracil
3 Brucea javanica
3 Thymol-Thymus vulgaris
3 Radiotherapy/Radiation
3 Ellagic acid
3 Ferulic acid
3 HydroxyTyrosol
3 Isobavachalcone
3 phytic acid, Inositol hexakisphosphate
3 Isoliquiritigenin
3 Luteolin
3 Lycopene
3 mebendazole
3 Magnetic Fields
3 Methylsulfonylmethane
3 Propyl gallate
3 α-Santalol/Sandalwood oil
2 1,8-Cineole
2 Artemisinin
2 Berbamine
2 Beta-Caryophyllene
2 temozolomide
2 brusatol
2 Boron
2 NTP, Non-Thermal Plasma,Cold Atmospheric Plasma
2 Cichoric acid / Chicoric acid
2 Cinnamon
2 Cucurbitacin
2 Cynaropicrin
2 Dichloroacetate
2 D-limonene
2 Dandelion Root
2 Echinacea
2 Ginkgo biloba-EGb 761
2 Eurycomanone
2 Flaxseed/Linseed
2 Gallic acid
2 Photodynamic Therapy
2 Hyperoside
2 Rutin
2 Indole-3-carbinol
2 isoquercitrin
2 Juglone
2 methylseleninic acid
2 Phenylbutyrate
2 Paclitaxel/Taxol
2 Piperine
2 Rosmarinic acid
2 salinomycin
2 Selenite (Sodium)
2 Ursolic acid
2 Urolithin
1 3-bromopyruvate
1 DTS(dibenzyl trisulphide) from Anamu
1 Anethole/trans-Anethole
1 Fennel Oil/Foeniculum vulgare
1 immunotherapy
1 Atorvastatin
1 Aloe anthraquinones
1 Baicalin
1 almonertinib
1 Bromelain
1 Bullatacin
1 Butyrate
1 Sorafenib (brand name Nexavar)
1 Cat’s Claw
1 Celastrol
1 Chlorogenic acid
1 Chlorophyllin
1 Coenzyme Q10
1 Carvone
1 Dichloroacetophenone(2,2-)
1 Date Fruit Extract
1 Diindolylmethane
1 Fenbendazole
1 Geldanamycin
1 Radicicol/monorden
1 Bortezomib
1 Flaxseed Oil
1 olaparib/LYNPARZA
1 Gemcitabine (Gemzar)
1 Ginkgolic acids
1 Genistein (soy isoflavone)
1 Ginkgolide B
1 Ginger/6-Shogaol/Gingerol
1 Gossypol/AT-101
1 Graviola
1 Hydroxycinnamic-acid
1 hydroxychloroquine
1 isoflavones
1 Isovitexin
1 tumor necrosis factor-related apoptosis-inducing ligand
1 Lapachol
1 Lasiodin
1 low dose naltrexone
1 Linalool
1 Lutein
1 Methylene blue
1 Matrine
1 Dordaviprone; Modeyso
1 Modified Citrus Pectin
1 Chemotherapy
1 Mistletoe/Viscum album Extracts
1 Mushroom Chaga, Inonotus obliquus
1 Myricetin
1 nelfinavir/Viracept
1 Oleuropein
1 Marjoram (Origanum majorana)
1 SonoDynamic Therapy UltraSound
1 Hyperthermia
1 Plumbagin
1 VitK3,menadione
1 Rauwolfia serpentina/Indian Snakeroot
1 buckwheat sprouts
1 Selenium NanoParticles
1 chitosan
1 Folic Acid, Vit B9
1 Osimertinib
1 Adagrasib
1 Terpinen-4-ol / Tea Tree Oil
1 Aflavin-3,3′-digallate
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:239  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page